Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
Kapil Bahl, Joe J. Senn, Olga Yuzhakov, Alex Bulychev, Luis A. Brito, Kimberly J. Hassett, Michael E. Laska, Mike Smith, Örn Almarsson, James Thompson, Amilcar Ribeiro, Mike Watson, Tal Zaks, Giuseppe Ciaramella
Abstract
Main text(Molecular Therapy 25, 1316–1327; June 2017)In the originally published version of this article, the sentence “LNP formulations were prepared using a modified procedure of a method previously described for siRNA” incorrectly cited reference 57. The correct reference for this sentence is reference 22.The authors regret this error. Main text(Molecular Therapy 25, 1316–1327; June 2017)In the originally published version of this article, the sentence “LNP formulations were prepared using a modified procedure of a method previously described for siRNA” incorrectly cited reference 57. The correct reference for this sentence is reference 22.The authors regret this error. (Molecular Therapy 25, 1316–1327; June 2017) In the originally published version of this article, the sentence “LNP formulations were prepared using a modified procedure of a method previously described for siRNA” incorrectly cited reference 57. The correct reference for this sentence is reference 22. The authors regret this error. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza VirusesBahl et al.Molecular TherapyApril 27, 2017In BriefPotential pandemic influenzas and the need for an effective, safe, and high-speed vaccine production platform have been widely discussed in the scientific community. Bahl et al. report the rapid and robust immune responses achieved against H10N8 and H7N9 viruses from modified mRNA vaccines with an acceptable safety profile. Full-Text PDF Open Access